Trexquant Investment LP Trims Position in DexCom, Inc. $DXCM

Key Points

• Trexquant Investment LP has reduced its stake in DexCom, Inc. by 46.5%, now owning 120,891 shares valued at approximately $8.26 million after selling 105,129 shares.
• In contrast, several other institutional investors, including Golden State Wealth Management LLC and Stonebridge Financial Group LLC, have significantly increased their stakes, indicating strong investor interest in DexCom.
• DexCom recently reported earnings of $0.48 per share, surpassing estimates and reflecting a 15.2% year-over-year revenue increase, with analysts maintaining a consensus rating of "Moderate Buy."

Trexquant Investment LP reduced its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 46.5% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 120,891 shares of the medical device company's stock after selling 105,129 shares during the quarter. Trexquant Investment LP's holdings in DexCom were worth $8,256,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Golden State Wealth Management LLC raised its holdings in DexCom by 211.2% in the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock worth $27,000 after purchasing an additional 264 shares in the last quarter. Private Trust Co. NA grew its holdings in shares of DexCom by 99.4% during the first quarter. Private Trust Co. NA now owns 672 shares of the medical device company's stock valued at $46,000 after buying an additional 335 shares during the last quarter. Farther Finance Advisors LLC boosted its holdings in shares of DexCom by 29.3% during the 1st quarter. Farther Finance Advisors LLC now owns 3,100 shares of the medical device company's stock valued at $209,000 after acquiring an additional 702 shares during the last quarter. Dynamic Advisor Solutions LLC boosted its holdings in shares of DexCom by 34.2% during the 1st quarter. Dynamic Advisor Solutions LLC now owns 5,235 shares of the medical device company's stock valued at $357,000 after acquiring an additional 1,333 shares during the last quarter. Finally, Stonebridge Financial Group LLC boosted its holdings in shares of DexCom by 944.5% during the 1st quarter. Stonebridge Financial Group LLC now owns 3,217 shares of the medical device company's stock valued at $220,000 after acquiring an additional 2,909 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, Director Nicholas Augustinos sold 3,672 shares of the stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $82.80, for a total transaction of $304,041.60. Following the transaction, the director owned 33,411 shares in the company, valued at $2,766,430.80. This trade represents a 9.90% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Mark G. Foletta sold 2,750 shares of the company's stock in a transaction on Monday, June 16th. The stock was sold at an average price of $83.13, for a total transaction of $228,607.50. Following the sale, the director directly owned 56,621 shares of the company's stock, valued at $4,706,903.73. The trade was a 4.63% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 15,722 shares of company stock worth $1,306,131. Corporate insiders own 0.32% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on DXCM shares. Mizuho raised their price objective on shares of DexCom from $95.00 to $100.00 and gave the stock an "outperform" rating in a report on Wednesday, July 16th. Barclays lifted their price objective on shares of DexCom from $93.00 to $98.00 and gave the company an "equal weight" rating in a research report on Wednesday, July 30th. Wall Street Zen downgraded shares of DexCom from a "strong-buy" rating to a "buy" rating in a research note on Sunday, August 10th. Oppenheimer boosted their price objective on shares of DexCom from $95.00 to $102.00 and gave the company an "outperform" rating in a research report on Thursday, July 31st. Finally, UBS Group boosted their target price on shares of DexCom from $105.00 to $106.00 and gave the company a "buy" rating in a research note on Thursday, July 31st. Three analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, DexCom presently has a consensus rating of "Moderate Buy" and an average target price of $99.89.

DexCom Stock Performance

DexCom stock traded up $1.79 during mid-day trading on Thursday, hitting $80.71. The company had a trading volume of 2,765,637 shares, compared to its average volume of 3,922,363. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48. DexCom, Inc. has a 12-month low of $57.52 and a 12-month high of $93.25. The company's fifty day moving average is $81.78 and its 200-day moving average is $79.27. The company has a market capitalization of $31.65 billion, a price-to-earnings ratio of 56.04, a P/E/G ratio of 1.58 and a beta of 1.48.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, topping the consensus estimate of $0.45 by $0.03. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The business had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. During the same quarter in the prior year, the firm posted $0.43 EPS. The business's quarterly revenue was up 15.2% compared to the same quarter last year. DexCom has set its FY 2025 guidance at EPS. Equities research analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.